Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TREZIX vs TENCON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Capsaicin is a TRPV1 receptor agonist that initially causes pain and neuropeptide release, followed by desensitization and depletion of substance P from sensory nerve terminals, reducing pain transmission. Hydrocodone is a mu-opioid receptor agonist, modulating pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, reducing prostaglandin synthesis and pain signaling.
Tencon is a combination product containing butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA activity at GABA-A receptors, producing sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception. Caffeine is a non-selective adenosine receptor antagonist, promoting alertness and vasoconstriction.
FDA-approved: Management of moderate to moderately severe pain where treatment with an opioid is appropriate,Off-label: Chronic pain syndromes, neuropathic pain
Tension headache,Migraine headache (off-label)
TREZIX (acetaminophen 320 mg, dichloralphenazone 100 mg, isometheptene mucate 65 mg) capsules: 2 capsules orally at onset of headache, then 1 capsule every hour until relief (maximum 5 capsules in 12 hours, 10 capsules in 24 hours). For migraine: 2 capsules orally at onset, then 1 capsule every hour as needed (maximum 5 capsules per attack).
5 mg orally once daily, increased to 10 mg if needed after 2 weeks; maximum 20 mg daily.
Terminal elimination half-life is approximately 2.5-3.5 hours for the parent compound; clinically, this necessitates dosing every 4-6 hours for sustained effect during wakefulness, but accumulation is minimal with normal hepatic and renal function.
Terminal half-life 2-4 hours; prolonged to 6-15 hours in renal impairment (Cr Cl <30 m L/min).
Hydrocodone: Hepatic metabolism via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone, respectively. Acetaminophen: Conjugation primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1), with minor CYP2E1 oxidation to NAPQI.
Butalbital is metabolized primarily by cytochrome P450 (CYP) enzymes. Acetaminophen is metabolized mainly in the liver via glucuronidation, sulfation, and oxidation (CYP2E1, CYP1A2, CYP3A4) to reactive metabolites that are conjugated with glutathione. Caffeine is metabolized by CYP1A2.
Renal excretion of metabolites (primarily as glucuronide conjugates and unchanged drug) accounts for approximately 55-65% of the dose; biliary/fecal elimination accounts for approximately 25-35%.
Primarily renal excretion (66-74% unchanged); biliary/fecal excretion (26-34%).
Approximately 35-40% bound to plasma proteins, primarily albumin.
25-30% bound to albumin.
Volume of distribution is approximately 3-4 L/kg, indicating extensive tissue distribution with penetration into the central nervous system.
0.3-0.5 L/kg; indicates distribution into total body water.
Oral bioavailability is approximately 50-70% due to first-pass hepatic metabolism.
Oral: 85-90% (extensive first-pass metabolism reduces bioavailability to 60-70% for parent drug, but active metabolite contributes).
No specific GFR-based dose adjustments available; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen and dichloralphenazone accumulation. Use with caution in moderate impairment (Cr Cl 30-60 m L/min); consider extending dosing interval to every 6-8 hours.
GFR >30 m L/min: no adjustment; GFR 15-30 m L/min: 5 mg once daily; GFR <15 m L/min: contraindicated.
Contraindicated in Child-Pugh class C (severe hepatic impairment). In Child-Pugh class A or B: reduce dose by 50% and monitor liver function; maximum acetaminophen daily dose should not exceed 2000 mg. Avoid in active liver disease.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: contraindicated.
Not recommended for children under 12 years due to lack of safety data. For adolescents 12-17 years: 1-2 capsules orally at onset, then 1 capsule every hour as needed (maximum 3 capsules in 12 hours). Weight-based dosing not established.
0.1 mg/kg orally once daily, maximum 5 mg; titrate after 2 weeks; maximum 10 mg.
Initiate with lower dose (1 capsule at onset) and monitor closely due to increased sensitivity to anticholinergic effects of dichloralphenazone. Maximum daily acetaminophen dose not to exceed 3000 mg. May require longer dosing intervals (every 6-8 hours).
Initiate at 2.5 mg orally once daily; increase cautiously to maximum 10 mg daily.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY (due to acetaminophen); RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks with CYP3A4 inhibitors or discontinuation; hepatotoxicity from acetaminophen overdose; hypersensitivity reactions; severe hypotension; gastrointestinal obstruction; seizures; serotonin syndrome with concomitant serotonergic drugs; impaired mental/physical abilities; adrenal insufficiency; androgen deficiency.
Hepatotoxicity with acetaminophen overdose; risk of dependence and withdrawal with butalbital (barbiturate); may impair ability to drive or operate machinery; avoid concurrent use with other acetaminophen-containing products; caution in patients with liver disease, renal impairment, or history of substance abuse.
Hypersensitivity to any ingredient; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings; known or suspected gastrointestinal obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (due to acetaminophen).
Known hypersensitivity to barbiturates, acetaminophen, or caffeine; porphyria; severe hepatic impairment; acute or chronic pain in patients with active alcoholism; concomitant use with other CNS depressants (relative contraindication).
Avoid alcohol. Limit caffeine from other sources (coffee, tea, soda) to prevent excessive stimulation. High-fat meals may delay absorption but do not significantly alter overall effect.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and additive central nervous system depression. Limit caffeine-containing foods and beverages (coffee, tea, cola, chocolate) to avoid excessive stimulant effects and potential caffeine toxicity.
TREZIX (acetaminophen, dichloralphenazone, isometheptene) is contraindicated in pregnancy. First trimester: risk of neural tube defects and other malformations due to acetaminophen? limited data but dichloralphenazone is a barbiturate derivative with known teratogenicity (cleft palate, cardiac defects). Second and third trimesters: barbiturates may cause neonatal dependence, withdrawal, and bleeding disorders (vitamin K deficiency). Late third trimester: maternal use of barbiturates may lead to neonatal respiratory depression and withdrawal. Avoid in all trimesters.
FDA Pregnancy Category B. No evidence of risk in first trimester based on animal studies; insufficient human data for second and third trimesters. Recommend use only if clearly needed.
No specific studies for TREZIX. Acetaminophen is compatible with breastfeeding (M/P ratio ~1.0). Dichloralphenazone (metabolized to trichloroethanol) and isometheptene: data lacking. Barbiturate metabolites may cause infant sedation, poor feeding, and withdrawal risk. Manufacturer advises caution; use alternative if possible.
Unknown if excreted in human milk. M/P ratio not determined. Use with caution in nursing mothers.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce drug levels. However, TREZIX is contraindicated due to teratogenicity and maternal/fetal risks; therefore, no dosing adjustment is recommended. Alternative therapy should be used.
No dose adjustment recommended for pregnancy; increased renal clearance in late pregnancy may require dose titration based on therapeutic drug monitoring.
TREZIX (acetaminophen, caffeine, and dihydrocodeine) is a fixed-dose combination analgesic with abuse potential; monitor for opioid-induced constipation and respiratory depression. Avoid exceeding 4 grams/day of acetaminophen due to hepatotoxicity risk. Caffeine may potentiate analgesic effects but can cause insomnia and anxiety. Discontinue prior to surgery to avoid withdrawal and respiratory complications.
Tencon is a combination analgesic containing acetaminophen, butalbital, and caffeine. It is indicated for tension headaches. Butalbital is a barbiturate with abuse potential; limit duration of use to avoid dependence. Acetaminophen hepatotoxicity risk increases with doses >4 g/day or in patients with hepatic impairment. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of barbiturate withdrawal (anxiety, tremor, seizures) if discontinued abruptly after prolonged use.
Take exactly as prescribed; do not increase dose or frequency without doctor approval.,Do not combine with other acetaminophen-containing products to avoid liver damage.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how TREZIX affects you.,Report severe constipation, difficulty breathing, or signs of allergic reaction immediately.,Do not stop suddenly; taper under medical supervision to prevent withdrawal.
Take exactly as prescribed; do not exceed recommended dose.,Avoid alcohol while taking this medication due to increased liver damage risk.,Do not take with other products containing acetaminophen (e.g., Tylenol, cold medicines).,This drug can be habit-forming; do not use longer than directed.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you.,Limit caffeine intake from other sources (coffee, tea, soda) to prevent overstimulation.,If you miss a dose, take it as soon as you remember; do not double the next dose.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TREZIX vs TENCON, answered by our medical review team.
TREZIX is a Barbiturate Combination Analgesic that works by Capsaicin is a TRPV1 receptor agonist that initially causes pain and neuropeptide release, followed by desensitization and depletion of substance P from sensory nerve terminals, reducing pain transmission. Hydrocodone is a mu-opioid receptor agonist, modulating pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the central nervous system, reducing prostaglandin synthesis and pain signaling.. TENCON is a Barbiturate combination analgesic that works by Tencon is a combination product containing butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA activity at GABA-A receptors, producing sedation and anxiolysis. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception. Caffeine is a non-selective adenosine receptor antagonist, promoting alertness and vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TREZIX and TENCON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TREZIX is: TREZIX (acetaminophen 320 mg, dichloralphenazone 100 mg, isometheptene mucate 65 mg) capsules: 2 capsules orally at onset of headache, then 1 capsule every hour until relief (maximum 5 capsules in 12 hours, 10 capsules in 24 hours). For migraine: 2 capsules orally at onset, then 1 capsule every hour as needed (maximum 5 capsules per attack).. The standard adult dose of TENCON is: 5 mg orally once daily, increased to 10 mg if needed after 2 weeks; maximum 20 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TREZIX and TENCON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TREZIX is classified as Category C. TREZIX (acetaminophen, dichloralphenazone, isometheptene) is contraindicated in pregnancy. First trimester: risk of neural tube defects and other malformations due to acetaminophen. TENCON is classified as Category C. FDA Pregnancy Category B. No evidence of risk in first trimester based on animal studies; insufficient human data for second and third trimesters. Recommend use only if clearly nee. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.